HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep^®/TaqMan^® test

Abstract

Comparative cost models were developed to assess cost-per-reportable result and annual costs for HIV-1 and HCV bDNA and AmpliPrep/TaqMan^® Test (PCR). Model cost components included kit, disposables, platform and related equipment, equipment service plan, equipment maintenance, equipment footprint, waste and labor. Model assessment was most cost-effective when run by bDNA with 36 or more clinical samples and PCR with 30 or fewer clinical samples. Lower costs are attained with maximum samples (84–168) run daily. Highest cost contributors include kit, platform and PCR proprietary disposables. Understanding component costs and the most economic use of HIV-1 and HCV viral load will aid in attaining lowest costs through selection of the appropriate assay and effective negotiations.

Keywords::

• AmpliPrep^® Taqman^® Test
• bDNA assay
• comparative study
• costs and cost analysis
• polymerase chain reaction
• real-time PCR
• viral load

Financial & competing interests disclosure

This work was supported by Siemens Medical Systems Diagnostics and recipients include Tarek Elbeik, Ralph Dalessandro and Scott Beringer. Support included consulting fees, bDNA kits, supplies and test samples. We have neither financial interests in nor affiliations with Siemens Medical Systems Diagnostics or its predecessor Bayer Diagnostics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.